Alliance for Aging Research Waxman/Hatch Position Mirrors BIO Stance
Executive Summary
The Alliance for Aging Research's support of patent restoration for clinical development time echoes BIO's position on Waxman/Hatch Act reform.
You may also be interested in...
Generic Litigation Costs Estimated To Be $150-$300 Mil. This Year
Generic drug-related litigation costs will be between $150 mil. and $300 mil. during 2000, attorney Robert Green (Leydig, Voit and Mayer, Chicago) told the UBS Warburg specialty pharmaceuticals conference in New York City May 24.
Generic Litigation Costs Estimated To Be $150-$300 Mil. This Year
Generic drug-related litigation costs will be between $150 mil. and $300 mil. during 2000, attorney Robert Green (Leydig, Voit and Mayer, Chicago) told the UBS Warburg specialty pharmaceuticals conference in New York City May 24.
Waxman/Hatch Debate Moves Forward: Generic Biologics Not Ruled Out
A generic approval process for biological product is being recognized as one item for consideration in reform of the Waxman/Hatch Act by the law's key sponsor in the Senate.